Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology R&D: Exploiting New Molecular Targets Is Challenge for 2003

Executive Summary

The next wave of cancer drugs entering late-stage development reflects the improved understanding of cancer biology and oncogenesis made possible by sophisticated genomics and bioinformatics technologies

You may also be interested in...



Genentech Eyes Top Oncology Spot By 2010; No Near-Term Avastin Competitor

Genentech believes the first competitor to its oncologic Avastin in the angiogenesis market is "years away.

Genentech Eyes Top Oncology Spot By 2010; No Near-Term Avastin Competitor

Genentech believes the first competitor to its oncologic Avastin in the angiogenesis market is "years away.

Genitope IPO Would Fund Phase III Cancer Vaccine Trials

Genitope plans to use proceeds from an initial public offering to fund enrollment of 360 patients in a pivotal study of the MyVax therapeutic cancer vaccine

UsernamePublicRestriction

Register

PS041028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel